
Gilead Sciences (GILD) Stock Forecast & Price Target
Gilead Sciences (GILD) Analyst Ratings
Bulls say
Gilead Sciences reported a robust financial performance, with fiscal year 2024 sales in its liver disease franchise reaching $3 billion, reflecting a year-over-year increase of 9%, driven by the successful launch of Livdelzi in primary biliary cholangitis. The company also experienced significant growth in its HIV segment, achieving sales of $19.6 billion for FY24, up 16% year-over-year, bolstered by higher demand and favorable market conditions, with Descovy's sales increasing 21% year-over-year to $616 million, surpassing expectations. Additionally, Gilead's commercial portfolio showed overall growth across multiple therapeutic areas, including a 12% year-over-year increase in oncology, further solidifying its positive outlook on future performance.
Bears say
Gilead Sciences faces a negative outlook primarily due to a projected decline in revenue from key products, including Veklury, which is expected to experience a continuous downward trend tied to decreasing COVID-19 hospitalizations, alongside anticipated declines in HIV revenue. The company's guidance suggests flat year-over-year revenue for FY25, with mid-teen percentage decreases quarterly, raising concerns about its ability to sustain growth amid increasing competition in both the hepatitis and oncology markets. Additionally, potential challenges in market penetration for CAR-T therapies and the execution of next-generation HIV treatments further compound the uncertainty surrounding Gilead's future financial performance.
This aggregate rating is based on analysts' research of Gilead Sciences and is not a guaranteed prediction by Public.com or investment advice.
Gilead Sciences (GILD) Analyst Forecast & Price Prediction
Start investing in Gilead Sciences (GILD)
Order type
Buy in
Order amount
Est. shares
0 shares